Literature DB >> 22901151

p63 cytoplasmic aberrance is associated with high prostate cancer stem cell expression.

Paranita Ferronika1, F X Ediati Triningsih, Ahmad Ghozali, Abraham Moeljono, Siti Rahmayanti, Arifah Nur Shadrina, Awang Emir Naim, Ivan Wudexi, Alfa Monica Arnurisa, Sandeep Tarman Nanwani, Ahmad Harijadi.   

Abstract

INTRODUCTION: Prostate cancer in Indonesia is the 3rd ranking cancer among males and the 5th rank for their cancer mortality. Prognostic markers that can identify aggressive prostate cancer in early stages and help select appropriate therapy to finally reduce the mortality are therefore urgently needed. It has been suggested that stem cells in the prostate gland have a role in initiation, progression, and metastasis of cancer, although controversy continues to exist. Maintenance of normal stem cell or reserve cell populations in several epithelia including prostate has been shown to be regulated by p63 and alteration of p63 expression is considered to have an oncogenic role in prostate cancer. We hypothesize that the expression of cytoplasmic aberrance of p63 is associated with high ALDH1A1 expression as a cancer stem cell marker, thus leading to progression of prostate cancer.
METHODS: Using a cross-sectional study during two years (2009-2010), a total of 79 paraffin embedded tissues of benign prostatic hyperplasia, PIN prostatic intraepithelial neoplasia, low and high Gleason score prostate cancer were investigated using immunohistochemistry. Associations between cytoplasmic p63 and ALDH1A1, as well as with pathological diagnosis, were analyzed by Chi-Square test using SPSS 15.0. Links of both markers with cell proliferation rate (KI-67) and apoptotic rate (cleaved caspase 3) were also analyzed by Kruskal-Wallis test.
RESULTS: The mean age of patient at the diagnosis is 70.0 years. Cytoplasmic aberrance of p63 was associated with ALDH1A1 expression (p<0.001) and both were found to have significant relationships with pathological diagnosis (including Gleason score), (p=0.006 and p<0.001 respectively). Moreover, it was also found that higher levels of cytoplasmic p63 were significantly associated with the frequency of proliferating cells and cells undergoing apoptosis in prostate cancers (p=0.001 and p=0.016 respectively).
CONCLUSION: p63 cytoplasmic aberrance is associated with high ALDH1A1 expression. These components are suggested to have an important role in prostate cancer progression and may be used as molecular markers.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22901151     DOI: 10.7314/apjcp.2012.13.5.1943

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  4 in total

1.  Altered expression of p63 isoforms and expansion of p63- and club cell secretory protein-positive epithelial cells in the lung as novel features of aging.

Authors:  Jutaro Fukumoto; Sahebgowda Sidramagowda Patil; Sudarshan Krishnamurthy; Smita Saji; Irene John; Venkata Ramireddy Narala; Helena Hernández-Cuervo; Matthew Alleyn; Mason T Breitzig; Lakshmi Galam; Ramani Soundararajan; Uddhav K Chaudhari; Barbara C Hansen; Richard F Lockey; Narasaiah Kolliputi
Journal:  Am J Physiol Cell Physiol       Date:  2019-01-16       Impact factor: 4.249

Review 2.  Current Stem Cell Biomarkers and Their Functional Mechanisms in Prostate Cancer.

Authors:  Kaile Zhang; Shukui Zhou; Leilei Wang; Jianlong Wang; Qingsong Zou; Weixin Zhao; Qiang Fu; Xiaolan Fang
Journal:  Int J Mol Sci       Date:  2016-07-19       Impact factor: 5.923

3.  Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.

Authors:  Giorgio Mauri; Elena Jachetti; Barbara Comuzzi; Matteo Dugo; Ivano Arioli; Silvia Miotti; Sabina Sangaletti; Emma Di Carlo; Claudio Tripodo; Mario P Colombo
Journal:  Oncotarget       Date:  2016-01-26

4.  The prognostic significance of p63 cytoplasmic expression in colorectal cancer. An immunohistochemical study.

Authors:  Abdulkader M Albasri; Mohammed A Elkablawy; Irfan A Ansari; Ahmed S Alhujaily; Amal A Khalil
Journal:  Saudi Med J       Date:  2019-05       Impact factor: 1.484

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.